ULBI Revenue Jumps 18% on Acquisition, But Net Income Plummets 75%

TL;DR

**ULBI's revenue growth is a mirage; the Electrochem acquisition is crushing their bottom line, making this a sell.**

AI Summary

ULTRALIFE CORP (ULBI) reported a significant increase in revenue for the nine-month period ended September 30, 2025, reaching $142,678 thousand, up from $120,604 thousand in the prior year, a 18.3% increase. However, net income attributable to Ultralife Corporation decreased substantially to $1,524 thousand for the nine-month period, compared to $6,118 thousand in the same period of 2024, representing a 75.1% decline. The company experienced an operating loss of $951 thousand for the three-month period ended September 30, 2025, a reversal from an operating income of $511 thousand in the prior year. This was largely driven by increased operating expenses, with R&D rising to $2,855 thousand from $2,101 thousand and SG&A increasing to $7,715 thousand from $6,070 thousand for the three-month period. The acquisition of Electrochem Solutions, Inc. on October 31, 2024, for $48,022 thousand, significantly impacted results, contributing $23,718 thousand in revenue and $2,118 thousand in net income before income taxes for the nine-month period ended September 30, 2025. The company also incurred $607 thousand in acquisition-related transaction costs during the nine-month period. Long-term debt, net, decreased to $46,518 thousand from $51,502 thousand at December 31, 2024, following payments on credit facilities totaling $4,063 thousand.

Why It Matters

ULTRALIFE's substantial revenue growth, primarily fueled by the Electrochem acquisition, signals an aggressive expansion strategy in the battery and energy products market. However, the sharp decline in net income and the shift to an operating loss in the latest quarter raise concerns about profitability and integration challenges, potentially impacting investor confidence. For employees, the acquisition could mean new opportunities or restructuring. Customers might benefit from an expanded product portfolio and strengthened competitive position, but the company's ability to realize promised synergies and gross margin expansion will be critical for long-term value creation in a competitive industry.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,247 thousand for the three-month period ended September 30, 2025, a significant deterioration from a net income of $279 thousand in the prior year. Furthermore, operating income for the nine-month period decreased by 44.7% to $4,704 thousand from $8,491 thousand, indicating a substantial decline in core operational profitability despite increased revenues.

Analyst Insight

Investors should exercise caution and closely monitor ULBI's next few quarters for signs of successful integration of Electrochem and a return to profitability. The significant drop in net income and operating loss suggest that the acquisition, while boosting revenue, is currently a drag on earnings. Consider holding off on new investments until clear evidence of synergy realization and improved margins emerges.

Financial Highlights

debt To Equity

0.34

revenue

$142,678

operating Margin

-2.2%

total Assets

$222,246

total Debt

$50,300

net Income

$1,524

eps

($0.07)

gross Margin

23.8%

cash Position

$9,260

revenue Growth

+18.3%

Revenue Breakdown

Key Numbers

• $142,678 — Total Revenues (9 months) (Increased from $120,604 thousand in 2024, an 18.3% increase.)
• $1,524 — Net Income Attributable to Ultralife Corporation (9 months) (Decreased from $6,118 thousand in 2024, a 75.1% decline.)
• ($1,247) — Net Loss (3 months) (Compared to net income of $279 thousand in the prior year, a significant reversal.)
• $48,022 — Electrochem Acquisition Price (Funded through a new credit agreement, impacting debt levels.)
• $23,718 — Electrochem Revenue Contribution (9 months) (Significant portion of the overall revenue increase.)
• $50,937 — Term Loan Outstanding (As of September 30, 2025, part of the new credit agreement.)
• $607 — Acquisition Transaction Costs (9 months) (Included in selling, general and administrative expense.)
• ($0.07) — Diluted EPS (3 months) (Compared to $0.02 in the prior year, indicating a loss per share.)

Key Players & Entities

• ULTRALIFE CORP (company) — registrant
• Electrochem Solutions, Inc. (company) — acquired entity
• KeyBank National Association (company) — lender and administrative agent
• Greatbatch Ltd. (company) — seller of Electrochem Solutions, Inc.
• FASB (regulator) — accounting standards setter
• SEC (regulator) — filing oversight
• NASDAQ (regulator) — exchange where ULBI is listed

FAQ

Risk Factors

• Deteriorating Profitability Despite Revenue Growth [high — financial]: While revenues increased by 18.3% to $142,678 thousand for the nine months ended September 30, 2025, net income attributable to Ultralife Corporation declined by 75.1% to $1,524 thousand. The company reported an operating loss of $951 thousand for the three-month period ended September 30, 2025, a reversal from an operating income of $511 thousand in the prior year.
• Increased Operating Expenses [high — operational]: Operating expenses rose significantly, with R&D expenses increasing to $2,855 thousand from $2,101 thousand and SG&A expenses growing to $7,715 thousand from $6,070 thousand for the three-month period ended September 30, 2025. This surge in expenses outpaced revenue growth.
• Acquisition Integration and Costs [medium — financial]: The acquisition of Electrochem Solutions, Inc. for $48,022 thousand on October 31, 2024, has impacted financial results. The company incurred $607 thousand in acquisition-related transaction costs during the nine-month period, which are included in SG&A expenses.
• Increased Debt Load Post-Acquisition [medium — financial]: The acquisition was funded through a new credit agreement, leading to a term loan outstanding of $50,937 thousand as of September 30, 2025. While net long-term debt decreased to $46,518 thousand from $51,502 thousand at December 31, 2024, due to payments, the new credit facility represents a significant financial obligation.

Industry Context

Ultralife Corporation operates in the battery and energy storage solutions market. This industry is characterized by rapid technological advancements, increasing demand for high-performance and long-lasting batteries, and a growing focus on sustainability and alternative energy sources. Competition is intense, with established players and emerging companies vying for market share.

Regulatory Implications

As a publicly traded company, Ultralife is subject to SEC regulations and reporting requirements, including timely filing of 10-Q and 10-K reports. Changes in accounting standards, such as ASU 2023-07 and ASU 2023-09, require careful implementation and disclosure. Compliance with environmental regulations related to battery production and disposal is also a consideration.

What Investors Should Do

1. Monitor operating expense trends closely.
2. Analyze the integration and performance of Electrochem Solutions, Inc.
3. Evaluate the company's debt management strategy.
4. Assess the sustainability of revenue growth.

Key Dates

• 2025-09-30: End of Nine-Month Period — Reporting period for the 10-Q, showing significant revenue growth but a sharp decline in net income.
• 2024-10-31: Acquisition of Electrochem Solutions, Inc. — This acquisition significantly impacted revenues and operating expenses, and was funded by new debt.
• 2025-09-30: Consolidated Balance Sheet Date — Reflects the financial position post-acquisition, with increased goodwill and a new term loan.
• 2025-09-30: Consolidated Statements of Income (Loss) Date — Shows the operating performance for the three and nine-month periods, highlighting the divergence between revenue and profitability.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. (Ultralife has an accumulated deficit of ($32,918) thousand as of September 30, 2025, indicating that cumulative losses exceed cumulative profits over its history.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (The acquisition of Electrochem Solutions, Inc. likely contributed to the increase in goodwill from $45,006 thousand at December 31, 2024, to $45,336 thousand at September 30, 2025.)

Non-controlling interest

The portion of equity of a subsidiary that is not attributable to the parent company. (Represents a small portion of equity (170 thousand as of September 30, 2025) and is related to subsidiaries where Ultralife does not own 100%.)

Diluted EPS

Earnings per share calculated using the weighted average number of outstanding common shares plus all dilutive potential common shares. (The company reported a diluted EPS of ($0.07) for the three-month period ended September 30, 2025, indicating a loss per share.)

Cost of products sold

The direct costs attributable to the production of goods sold by a company. (Increased significantly to $108,713 thousand for the nine-month period, growing faster than revenue and contributing to margin compression.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Ultralife Corporation has seen a substantial 18.3% increase in revenue, reaching $142,678 thousand. However, this top-line growth has not translated to the bottom line, with net income attributable to Ultralife Corporation plummeting by 75.1% to $1,524 thousand. This divergence is primarily due to a significant increase in operating expenses, particularly R&D and SG&A, and the impact of the recent acquisition of Electrochem Solutions, Inc. The company has also shifted from an operating income to an operating loss in the latest three-month period, a concerning trend.

Key Financial Figures

• $0.10 — ection 12(b) of the Act: Common Stock, $0.10 par value per share ULBI NASDAQ (

Filing Documents

• ulbi20250930_10q.htm (10-Q) — 1324KB
• ex_886590.htm (EX-31.1) — 13KB
• ex_886591.htm (EX-31.2) — 13KB
• ex_886592.htm (EX-32) — 9KB
• 0001437749-25-035475.txt ( ) — 7046KB
• ulbi-20250930.xsd (EX-101.SCH) — 52KB
• ulbi-20250930_def.xml (EX-101.DEF) — 368KB
• ulbi-20250930_lab.xml (EX-101.LAB) — 319KB
• ulbi-20250930_pre.xml (EX-101.PRE) — 394KB
• ulbi-20250930_cal.xml (EX-101.CAL) — 53KB
• ulbi20250930_10q_htm.xml (XML) — 1383KB

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION Item 6. Exhibits 30

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONSOLIDATED FINANCIAL STATEMENTS

Item 1. CONSOLIDATED FINANCIAL STATEMENTS ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In Thousands except share amounts) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash $ 9,260 $ 6,854 Trade accounts receivable, net of allowance for expected credit losses of $ 418 and $ 384 , respectively 30,929 29,370 Inventories, net 52,747 51,363 Prepaid expenses and other current assets 7,683 9,573 Total current assets 100,619 97,160 Property, plant and equipment, net 40,536 40,485 Goodwill 45,336 45,006 Other intangible assets, net 23,407 24,557 Deferred income taxes, net 8,212 8,413 Other noncurrent assets 4,136 4,830 Total assets $ 222,246 $ 220,451 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities: Accounts payable $ 14,164 $ 14,160 Current portion of long-term debt 3,781 2,750 Accrued compensation and related benefits 2,935 2,911 Accrued expenses and other current liabilities 12,818 9,470 Total current liabilities 33,698 29,291 Long-term debt, net 46,518 51,502 Deferred income taxes 1,358 1,443 Other noncurrent liabilities 3,239 4,028 Total liabilities 84,813 86,264 Commitments and contingencies (Note 9) Stockholders' equity: Preferred stock – par value $ .10 per share; authorized 1,000,000 shares; none issued - - Common stock – par value $ .10 per share; authorized 40,000,000 shares; issued – 21,085,061 shares at September 30, 2025 and 21,069,079 shares at December 31, 2024; outstanding – 16,648,947 shares at September 30, 2025 and 16,632,965 shares at December 31, 2024 2,109 2,107 Capital in excess of par value 192,622 191,828 Accumulated deficit ( 32,918 ) ( 34,442 ) Accumulated other comprehensive loss ( 3,058 ) ( 4,006 ) Treasury stock - at cost; 4,436,114 shares at September 30, 2025 and 4,436,114 shares at December 31, 2024 ( 21,492 ) ( 21,492

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (In thousands except share and per share amounts) (Unaudited) 1. BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the "Company" or "Ultralife") have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2024. The December 31, 2024 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP. Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation. Recently Adopted Accounting Guidance In November 2023, the FASB issued ASU 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures" to expand the disclosure requirements for reportable segments. The standard expands reportable segment disclosure requirements for public business entities primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment operating profit (loss). This standard is effective for fiscal years beginning after December 15

View Full Filing

View this 10-Q filing on SEC EDGAR